Pantoprazole

Limits on what this shows

• Null findings: No study measuring mitochondrial function in pantoprazole-treated non-cancer human tissue was located.
• At-risk subgroups: None identified.

Regulatory status

Not addressed. The label's mechanism is covalent binding to the gastric (H+, K+)-ATPase, a proton pump distinct from mitochondrial machinery; the intended gastric effect is not graded here (Hard Rule 2) [1].

Evidence (Tier B)

Glioma cell lines: pantoprazole induced mitochondrial membrane depolarization, increased reactive oxygen species, activated caspase-3 and suppressed NF-kB signaling [31]. Cancer cell lines: pantoprazole reduced proteasome subunit expression and sensitized cells to BCL-2 inhibitors under mitochondrial stress [32]. Rat brain, 20 mg/kg/day for 12 weeks: higher pro-apoptotic protein ratios, particularly in motor cortex [29].

Mechanism

Mitochondrial apoptosis pathway in transformed cells [31]. Mechanism E present only in vitro.

Counter-evidence held on record

Counter-evidence on record Cancer-cell models do not predict effects in healthy tissue, and exposure relative to clinical plasma levels was not assessed from the abstracts opened. The 12-week rat study is the only chronic in vivo observation and it did not measure mitochondrial function directly. Framing caution No mitochondrial-support supplement is recommended. Shares evidence with Oxidative stress; see Overlap map.

Limits on what this shows

• Null findings: No human study measuring oxidative stress markers in pantoprazole users was located.
• At-risk subgroups: None identified.

Regulatory status

Not addressed in the label excerpts opened [1].

Evidence (Tier B, pantoprazole)

Mice with cisplatin nephrotoxicity: pantoprazole raised superoxide dismutase, catalase and glutathione and lowered lipid peroxidation [27]. Rats with renal ischemia-reperfusion: 18 mg/kg lowered malondialdehyde and TLR4 expression [28]. In vitro Fenton-type assay: PPIs including pantoprazole scavenged hydroxyl radicals [30]. Opposite direction: female Wistar rats given 20 mg/kg/day by gavage for 12 weeks had higher malondialdehyde and lower antioxidant defenses in motor cortex and cerebellum, with gavage itself contributing to some effects [29]. Glioma cells in vitro: increased reactive oxygen species [31].

Mechanism

Direct radical scavenging attributed to the sulfoxide and thioether groups [30]; pro-oxidant effects in cancer cell lines and a chronic rat model [29][31]. Human relevance unproven.

Counter-evidence held on record

Counter-evidence on record The same drug appears protective in injury models and harmful in a chronic model, so no single direction can be attributed. Doses (up to 36 mg/kg in rats) are not directly comparable with human dosing. Framing caution Mechanistic only. This is neither an antioxidant-depletion claim nor a benefit claim. No antioxidant supplement is recommended.

Limits on what this shows

• Null findings: Pantoprazole-only primary care study (n=30 vs 36): serum iron 85.9 vs 83.4 ug/dL, p=0.71; ferritin 170.0 vs 364.5 ng/mL, p=0.14 [3]. 12-month prospective study: iron deficiency developed in 3.8% of PPI users, judged not clinically significant [16]. 255-patient cross-sectional study: iron and ferritin deficiency not associated with PPI type or duration (pantoprazole not named in the abstract) [33].
• At-risk subgroups: Kidney transplant recipients on higher omeprazole-equivalent doses [20]; patients taking oral iron salts (label interaction).

Regulatory status

Label section 7 lists iron salts among drugs whose absorption depends on gastric pH [1]. The label excerpts opened list no iron-deficiency adverse reaction.

Population evidence

Randomized controlled trial, thalassemia major and intermedia, 55 completers, pantoprazole 40 mg/day for 6 months added to chelators: serum ferritin fell from 1444 +/- 613 to 1197 +/- 956 (units as printed in source), within-group P<0.001; myocardial T2* unchanged [19]. Kidney transplant cohort, 724 recipients: any PPI use iron deficiency OR 2.02 (1.36-2.98); pantoprazole alone did not reach significance and showed lower odds than omeprazole or esomeprazole [20]. Cross-sectional pilot, 37 long-term PPI users (18 on pantoprazole; 3 to 10 years) vs 30 healthy controls: serum iron 16.3 vs 23.4 umol/L and hemoglobin 12.5 vs 14.3 g/dL, both p<0.001; ferritin not measured [18].

Mechanism

Acid-dependent solubility and absorption of non-heme iron (mechanism A), consistent with the label's pH-dependent absorption entry [1].

Counter-evidence held on record

Counter-evidence on record The pilot used healthy controls and mixed PPIs, with confounding by indication and no ferritin [18]. The controlled pantoprazole-only study found no iron or ferritin difference [3]. The transplant cohort's pantoprazole-alone estimate was not significant [20]. Low hemoglobin or anemia is an outcome, not iron deficiency, unless iron indices are measured (Hard Rule 2). Framing caution The pantoprazole-specific trial shows a fall in stores in iron overload, so for some patients lower iron uptake is the intended clinical direction. Unneeded iron supplementation would be the hazard, not the remedy. No dose is recommended.

Limits on what this shows

• Null findings: A narrative review reports copper levels were not observed to decrease with PPI use [22]. In the zinc experiment, serum copper changed little with zinc supplementation in controls (91 to 88 mcg/dL, P=0.35); no PPI-versus-control copper comparison was reported [21].
• At-risk subgroups: None identified.

Regulatory status

No copper statement in the label excerpts opened [1].

Population evidence

Cross-sectional pilot, 37 PPI users for 3 to 10 years (pantoprazole 18, esomeprazole 9, omeprazole 7, dexlansoprazole 2, lansoprazole 1) vs 30 healthy controls: copper 1.14 +/- 0.25 vs 0.97 +/- 0.22 mg/L, p<0.001 (higher in PPI users) [18].

Mechanism

None named. The pilot authors suggest mechanisms beyond gastric pH [18]. Mechanism A is not established for copper.

Counter-evidence held on record

Counter-evidence on record One small cross-sectional pilot with healthy controls (confounding by indication and disease not excluded), mixed PPIs, no replication. A single cross-sectional comparison cannot show that the drug caused the difference. Copper is kept as an independent entry and is not merged with iron or zinc, although [18] supplies all three measurements (see Overlap map). Framing caution This is a reverse-direction, unreplicated observation. It is neither a depletion nor a retention claim. Copper supplementation would be the hazard, not the remedy; none is recommended.

Limits on what this shows

• Null findings: Individual cohorts in [23] did not reach significance for diversity before meta-analysis; pooled alpha-diversity change in [24] was not significant.
• At-risk subgroups: Not defined for pantoprazole. An 8-week pre-post study of esomeprazole, rabeprazole or lansoprazole (not pantoprazole) found increased Lactobacillus and Streptococcus counts [25].

Regulatory status

Not addressed as a nutrient or microbiome effect in the label excerpts opened [1].

Population evidence

Class extrapolation: three Dutch cohorts, 1,815 individuals, 211 PPI users (11.6%); PPI use was scored if participants used omeprazole, esomeprazole, pantoprazole, lansoprazole, dexlansoprazole or rabeprazole, but the number of pantoprazole users is not reported. Meta-analysis: Shannon diversity p=0.01, richness p=0.02; 92 of 460 taxa altered; oral-cavity taxa (Rothia, Streptococcaceae), Enterococcus and Escherichia coli increased. Cross-sectional [23]. Meta-analysis of four 16S studies, 292 stool samples: pooled alpha-diversity SMD -0.17 (-0.41 to 0.07), not significant; beta-diversity differed; Ruminococcaceae and Lachnospiraceae fell; strong between-study heterogeneity; pantoprazole not stratified [24].

Mechanism

Raised gastric pH permitting oral and upper-tract organisms to reach the lower gut (mechanism G, proposed in [23]; not directly demonstrated). Consequence for nutrient synthesis is unmeasured.

Counter-evidence held on record

Counter-evidence on record Cross-sectional design with confounding by indication (cohorts included IBD and IBS patients); no dose or duration analysis; pantoprazole contribution not separable. The pre-post study [25] and a lansoprazole rat editorial [26] excluded pantoprazole and are cited only as direction-of-effect context. Framing caution A composition finding at class level, not a nutrient deficiency and not a statement about health harm from pantoprazole specifically. Probiotic use is not recommended here.

Limits on what this shows

• Null findings: Hemoglobin and MCV similar in the pantoprazole-only study [3]. No arterial oxygenation or tissue oxygen delivery data located.
• At-risk subgroups: Not defined.

Regulatory status

Label postmarketing reports include pancytopenia and agranulocytosis under hematologic disorders; these are idiosyncratic events and not an oxygen-delivery finding [1].

Population evidence

Pantoprazole 40 mg/day for more than 12 months (n=30) vs non-users (n=36): red blood cells 4.26 +/- 0.52 vs 4.86 +/- 0.36 x10^6, p<0.001; hemoglobin and MCV similar [3]. Pilot of 37 long-term PPI users (18 pantoprazole) vs 30 healthy controls: hemoglobin 12.5 vs 14.3 g/dL, p<0.001, with the authors attributing this to iron deficiency (iron deficiency itself was not confirmed by ferritin) [18].

Mechanism

If any, secondary to reduced iron absorption (see Iron). No direct mechanism for oxygen transport or utilization was found.

Counter-evidence held on record

Counter-evidence on record Anemia and low hemoglobin are outcomes, not nutrient deficiencies (Hard Rule 2); the pilot used healthy controls and mixed PPIs, and the pantoprazole-only study found hemoglobin unchanged. Kept independent from ATP production (Hard Rule 7). Framing caution Not a claim that pantoprazole impairs oxygen delivery. Iron would be a hazard in patients without confirmed deficiency; no dose is recommended.

Limits on what this shows

• Why no grade: The dual condition in Step 7 is met: (1) no Tier B or Tier C evidence supports even a yellow grade, because no pantoprazole or PPI-class study measuring ATP or respiration was found; the only pantoprazole mitochondrial data are apoptosis and membrane-depolarization findings in cancer cells, which are graded under Mitochondrial burden and do not measure ATP [31]; (2) none of the consumer pages opened made an energy, fatigue or ATP claim for pantoprazole [35][36], so there is no claim to rebut as white. This is a disclosed gap, not a finding of safety.

Channels tried and outcome

PubMed HTML listings (worked): "pantoprazole oxidative phosphorylation" returned a clean zero; "pantoprazole ATP production OR ATP levels" and "pantoprazole bioenergetics OR cellular energy OR mitochondrial respiration" returned thousands of non-pantoprazole results with no pantoprazole item on page 1; "pantoprazole mitochondrial" returned 6 results, none measuring ATP. DailyMed/FDA label (worked via fetch tool): opened in full for relevant sections; no energy or ATP effect described. Crossref (single-DOI lookup worked; search blocked by curl, 403): not usable for discovery. OpenAlex: single-record lookup worked; search returned 429. Europe PMC: 429 (fetch tool) and 403 (direct). Semantic Scholar: 403 (direct) and 429 (fetch tool). Unpaywall: 403 direct; open-access lookup worked but is not a search tool. Direct publisher pages: MDPI, ScienceDirect, Wiley and Springer pages opened for some articles, with 403 or bot-check responses for others. Web search: the session search budget (200 of 200) was exhausted before any ATP-specific web query could be run.

Gap type

Genuine absence on the PubMed channel (one clean zero and two unproductive phrasings), but search breadth was limited by tooling: OpenAlex and Europe PMC search, Semantic Scholar and web search were unavailable. A later revision should re-check this category with those channels.

Counter-evidence held on record

Counter-evidence on record Not applicable; no data to counter. Kept independent from Oxygen delivery/utilization and Mitochondrial burden as required. Framing caution Do not read this entry as reassurance. It states only that no evidence was found in the channels that could be searched.